As the transition from 2D to 3D cell cultures, or organoids, as the gold standard for modeling basic biology and disease continues, these models are being utilized in ever more intricate and impactful ways.This episode covers the rise of organoids and their advantages over 2D cell cultures, before exploring just how representative these models are becoming and their new applications in drug discovery. To find out all this and more, I speak to Oksana Sirenko, Senior Scientist at Molecular Devices, who works extensively with the company's organoid model development programs. Oksana reveals the potential of these models in cancer therapeutics, driven forward by new patient-derived organoids, and notes the challenges presented by imaging these thicker, 3D models. We also explore the potential discoveries that can be unlocked by combining organoids with organ-on-a-chip models.Contents:What are organoids? 02:10-03:20Functions replicated by organoids? 3:20-04:00What are the advantages of 3D over 2D cell cultures? 04:00-05:40Just how representative are these models? 04:40-07:10Intestinal organoid formation 07:10-08:50The most exciting application of organoids 08:50-10:10Organoids in drug development 10:10-11:20Methodology of organoids in drug screening studies 11:20-13:30Examples of organoids in cancer drug discovery: 13:30-16:00Limitations of patient-derived and regular organoid models: 16:00-17:50Body-on-a-chip concepts and examples: 17:50-22:00Challenges posed by organoids for drug discovery: 22:00-24:20Techniques improving organoid models and analysis: 24:20-25:50Imaging organoid models: 25:50-26:55Tips for best practice when working with organoids: 26:55-28:20Organoid method development: 28:20-31:10One thing to improve organoid models or analysis for drug screening: 31:10-33:07To find out more about the research and solutions discussed in this episode visit: www.moleculardevices.com/TechTalk8. Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.